Mirum Pharmaceuticals, Inc. (MIRM) FY2026 YTD Q2 P&L / Income Statement

Mirum Pharmaceuticals, Inc. (MIRM) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Product sales, net

336,125,000 US dollars

Total operating expenses

1,168,127,000 US dollars

Loss from operations

negative 832,002,000 US dollars

Other income (expense), net (calculated)

negative 23,216,000 US dollars

Net loss before provision for income taxes

negative 855,218,000 US dollars

Provision for income taxes

2,164,000 US dollars

Net loss

negative 857,382,000 US dollars

Livmarli

242,525,000 US dollars

Bile Acid Medicines

93,600,000 US dollars

Total operating expenses

1,168,127,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.